Jefferies Financial Group Issues Pessimistic Forecast for Kura Oncology (NASDAQ:KURA) Stock Price

Kura Oncology (NASDAQ:KURA) had its target price lowered by Jefferies Financial Group from $32.00 to $28.00 in a report released on Thursday morning,Benzinga reports. Jefferies Financial Group currently has a buy rating on the stock.

KURA has been the subject of several other research reports. Lifesci Capital raised Kura Oncology to a “strong-buy” rating in a research note on Tuesday, October 22nd. Wedbush reiterated an “outperform” rating and issued a $37.00 target price on shares of Kura Oncology in a report on Monday, November 4th. HC Wainwright upped their target price on Kura Oncology from $32.00 to $37.00 and gave the company a “buy” rating in a report on Thursday. StockNews.com cut Kura Oncology from a “hold” rating to a “sell” rating in a report on Wednesday, November 20th. Finally, JMP Securities restated a “market outperform” rating and set a $32.00 price target on shares of Kura Oncology in a report on Tuesday, November 19th. One analyst has rated the stock with a sell rating, one has issued a hold rating, nine have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, Kura Oncology currently has a consensus rating of “Moderate Buy” and a consensus price target of $29.38.

Kura Oncology Stock Up 7.4 %

Shares of NASDAQ KURA opened at $10.80 on Thursday. The company has a debt-to-equity ratio of 0.02, a quick ratio of 11.47 and a current ratio of 11.47. Kura Oncology has a 52 week low of $9.06 and a 52 week high of $24.17. The stock has a market capitalization of $839.81 million, a P/E ratio of -4.58 and a beta of 0.86. The stock’s fifty day moving average is $17.88 and its 200 day moving average is $19.67.

Institutional Investors Weigh In On Kura Oncology

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. nVerses Capital LLC purchased a new stake in shares of Kura Oncology during the 3rd quarter valued at $25,000. ProShare Advisors LLC boosted its stake in Kura Oncology by 9.7% in the 1st quarter. ProShare Advisors LLC now owns 18,014 shares of the company’s stock worth $384,000 after purchasing an additional 1,588 shares during the period. Aaron Wealth Advisors LLC boosted its stake in Kura Oncology by 2.4% in the 2nd quarter. Aaron Wealth Advisors LLC now owns 70,148 shares of the company’s stock worth $1,444,000 after purchasing an additional 1,673 shares during the period. The Manufacturers Life Insurance Company raised its holdings in shares of Kura Oncology by 5.4% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 38,536 shares of the company’s stock valued at $793,000 after acquiring an additional 1,976 shares in the last quarter. Finally, Hsbc Holdings PLC raised its holdings in shares of Kura Oncology by 13.4% in the 2nd quarter. Hsbc Holdings PLC now owns 18,300 shares of the company’s stock valued at $374,000 after acquiring an additional 2,167 shares in the last quarter.

Kura Oncology Company Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.